Survival curves of days until likely infection, with animals from antibody treatment groups clustered according to whether they received treatment with the fully neutralizing ITS103.01 mAb (+ITS103.01 mAb) or lacked ITS103.01 in the delivered mAbs (ITS103.01 mAb). Group 1 (control) animals are shown separately. In d and e , survival curves for the control and each mAb treatment group or cluster were compared using a two-tailed Wilcoxon test; significant differences ( P < 0.05, Bonferroni-corrected for multiple comparisons) are indicated for each mAb treatment (by legend colour) versus control.
